trilaciclib
Restricted to use by Oncology in the outpatient setting for FDA approved indications. Reimbursement and insurance certification or PAP eligibility will be reviewed prior to initiation of therapy.
Reviewed: March 2022 (Cosela)
Trilaciclib (Cosela)
Restricted to use by Oncology in the outpatient setting for FDA approved indications. Reimbursement and insurance certification or PAP eligibility will be reviewed prior to initiation of therapy.
Reviewed: March 2022 (Cosela)
Trilaciclib (Cosela)